about
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionA dynamic neuro-fuzzy model providing bio-state estimation and prognosis prediction for wearable intelligent assistantsIn silico toxicology: computational methods for the prediction of chemical toxicityPharmacokinetic/pharmacodynamic modeling in inflammationImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchPF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsUnderstanding and applying pharmacometric modelling and simulation in clinical practice and researchIn silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammationIntegrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease.Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsDisease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.Multiscale model for the assessment of autonomic dysfunction in human endotoxemia.Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats.Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposurePharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesUse of pharmacokinetic data below lower limit of quantitation valuesSurinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humansAn agent-based model of cellular dynamics and circadian variability in human endotoxemia.Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.Stochastic modeling of systems mapping in pharmacogenomics.Modeling endotoxin-induced systemic inflammation using an indirect response approach.Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsPKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsTranslating slow-binding inhibition kinetics into cellular and in vivo effectsLogic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki ratsADME of biologics-what have we learned from small molecules?Advancing In Vitro-In Vivo Extrapolations of Mechanism-Specific Toxicity Data Through Toxicokinetic Modeling.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development
P2860
Q24595639-503F6540-0471-4844-ADDA-A573B1D56A0BQ24816707-319EB590-64E0-4624-89E3-B31BA758287DQ26749472-651274A6-A425-4E13-9148-E609D2DDE9F3Q26830621-966ED8FD-BE4B-49AD-9605-95F7EB2A9FE7Q27024682-38090C69-C62B-4645-9973-BE08EA836F0BQ27853138-F5B5A00C-3C9A-4D80-82C2-68FF8E15EC3BQ28468334-C6AC6957-71CF-4CB5-87CE-05BEDB69A824Q28474971-B99CD76B-C1D4-4150-B703-E6B4AA6465F7Q30422271-43624D79-0B58-4F5F-84F5-D8A2F01BB020Q30806067-662BEC0B-B114-44C0-BEA7-2FBF2E262738Q33611516-5313038B-D442-42F2-81B5-2E6AD822968FQ33726385-9E2E82DC-E744-4CAA-98B3-8014E1F3FB90Q33876563-FC529F67-79B3-401A-B005-1ED65AFCDFF1Q33906751-9AB7ABC8-690E-4382-A4B0-4AA4FB698908Q33924871-22E69262-C182-41E7-B7B9-1D67726395DFQ34070221-650C6864-E1E0-4529-A4CC-67DC92AB419AQ34143269-1ACF15F4-3475-4304-B51A-CDF47A833CC5Q34293586-B1C90431-DEFD-4E6F-B9F6-56FE6BADDFAFQ34293689-212617E6-5B95-4F70-B2DF-EBAD480543D5Q34315916-2F6157D2-6E78-457C-AAB8-9C229DDB2E9BQ34320289-4B34179A-5F99-446E-8820-9D387B57BF66Q34576707-78976342-CCCC-412D-9151-6A65538EA994Q34592125-FA5990AB-459C-49D6-8579-D3173FE95E4EQ34599933-79D79436-8104-4D33-A532-2FAD497CF5ACQ34611156-FC764217-0D10-4132-B4F6-35AEAC92312BQ34702329-3050F5E5-D286-4119-9AE4-1B4BFAF0567DQ34737629-13E3F16C-3685-45B7-B23E-4D28D2484C26Q35001424-8F103654-8688-49BE-AD3C-E871D2E49AC4Q35096292-E3451D14-F47E-40DF-88A3-945911335C40Q35104052-DC3466C1-806C-4503-AA50-90121781CA27Q35858617-1F3A3588-6D4E-4E91-9C62-BA52662F5037Q35865449-3DE02EE8-1BB2-4E91-A9E7-9E939E59B0E2Q35919697-ED4DACDA-A92A-4676-B3E0-3749B6B67738Q35954896-0C406F60-690C-4438-8A32-F75F65E1B910Q35962054-964BBADF-D15B-4211-A68A-9BE7E94340D8Q35996694-6357A7C1-2543-4984-8DA0-08F86AA77A22Q36065589-ADACC39E-0A38-4FE9-A63D-C040AF8C8646Q36130508-F7955F0A-787B-4537-A214-ADD5A1A5B1E6Q36354544-907F392E-A715-4E09-9315-8C32B79FCE1BQ36861319-E8168CC7-5C9A-4981-BC55-FE409AB3DAA7
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Diversity of mechanism-based pharmacodynamic models.
@ast
Diversity of mechanism-based pharmacodynamic models.
@en
type
label
Diversity of mechanism-based pharmacodynamic models.
@ast
Diversity of mechanism-based pharmacodynamic models.
@en
prefLabel
Diversity of mechanism-based pharmacodynamic models.
@ast
Diversity of mechanism-based pharmacodynamic models.
@en
P356
P1476
Diversity of mechanism-based pharmacodynamic models.
@en
P2093
Donald E Mager
William J Jusko
P304
P356
10.1124/DMD.31.5.510
P577
2003-05-01T00:00:00Z